Voest EE - Search Results

1

Patients with Biallelic BRCA1/2 Inactivation Respond to Olaparib Treatment Across Histologic Tumor Types.

van der Wijngaart H, Hoes LR, van Berge Henegouwen JM, van der Velden DL, Zeverijn LJ, Roepman P, van Werkhoven E, de Leng WWJ, Jansen AML, Mehra N, Robbrecht DGJ, Labots M, de Groot DJA, Hoeben A, Hamberg P, Gelderblom H, Voest EE, Verheul HMW. van der Wijngaart H, et al. Among authors: voest ee. Clin Cancer Res. 2021 Nov 15;27(22):6106-6114. doi: 10.1158/1078-0432.CCR-21-1104. Epub 2021 Sep 2. Clin Cancer Res. 2021. PMID: 34475104

2

Phase I dose-escalation study of the safety and pharmacokinetics of atrasentan: an endothelin receptor antagonist for refractory prostate cancer.

Zonnenberg BA, Groenewegen G, Janus TJ, Leahy TW, Humerickhouse RA, Isaacson JD, Carr RA, Voest E. Zonnenberg BA, et al. Clin Cancer Res. 2003 Aug 1;9(8):2965-72. Clin Cancer Res. 2003. PMID: 12912943 Clinical Trial.

3

Recombinant human angiostatin by twice-daily subcutaneous injection in advanced cancer: a pharmacokinetic and long-term safety study.

Beerepoot LV, Witteveen EO, Groenewegen G, Fogler WE, Sim BK, Sidor C, Zonnenberg BA, Schramel F, Gebbink MF, Voest EE. Beerepoot LV, et al. Among authors: voest ee. Clin Cancer Res. 2003 Sep 15;9(11):4025-33. Clin Cancer Res. 2003. PMID: 14519623 Clinical Trial.

4

Increased levels of viable circulating endothelial cells are an indicator of progressive disease in cancer patients.

Beerepoot LV, Mehra N, Vermaat JS, Zonnenberg BA, Gebbink MF, Voest EE. Beerepoot LV, et al. Among authors: voest ee. Ann Oncol. 2004 Jan;15(1):139-45. doi: 10.1093/annonc/mdh017. Ann Oncol. 2004. PMID: 14679134 Free article.

5

Are tumours angiogenesis-dependent?

Verheul HM, Voest EE, Schlingemann RO. Verheul HM, et al. Among authors: voest ee. J Pathol. 2004 Jan;202(1):5-13. doi: 10.1002/path.1473. J Pathol. 2004. PMID: 14694516 Review.

6

Predicting early failure after adjuvant chemotherapy in high-risk breast cancer patients with extensive lymph node involvement.

Faneyte IF, Peterse JL, Van Tinteren H, Pronk C, Bontenbal M, Beex LV, van der Wall E, Richel DJ, Nooij MA, Voest EE, Hupperets P, Ten Vergert EM, de Vries EG, Rodenhuis S, van de Vijver MJ. Faneyte IF, et al. Among authors: voest ee. Clin Cancer Res. 2004 Jul 1;10(13):4457-63. doi: 10.1158/1078-0432.CCR-03-0054. Clin Cancer Res. 2004. PMID: 15240537 Clinical Trial.

7

Circulating endothelial cells in cancer patients do not express tissue factor.

Beerepoot LV, Mehra N, Linschoten F, Jorna AS, Lisman T, Verheul HM, Voest EE. Beerepoot LV, et al. Among authors: voest ee. Cancer Lett. 2004 Sep 30;213(2):241-8. doi: 10.1016/j.canlet.2004.04.019. Cancer Lett. 2004. PMID: 15327840

8

The von Hippel-Lindau tumor suppressor protein influences microtubule dynamics at the cell periphery.

Lolkema MP, Mehra N, Jorna AS, van Beest M, Giles RH, Voest EE. Lolkema MP, et al. Among authors: voest ee. Exp Cell Res. 2004 Dec 10;301(2):139-46. doi: 10.1016/j.yexcr.2004.07.016. Exp Cell Res. 2004. PMID: 15530850

9

Progenitor marker CD133 mRNA is elevated in peripheral blood of cancer patients with bone metastases.

Mehra N, Penning M, Maas J, Beerepoot LV, van Daal N, van Gils CH, Giles RH, Voest EE. Mehra N, et al. Among authors: voest ee. Clin Cancer Res. 2006 Aug 15;12(16):4859-66. doi: 10.1158/1078-0432.CCR-06-0422. Clin Cancer Res. 2006. PMID: 16914572

10

Circulating mitochondrial nucleic acids have prognostic value for survival in patients with advanced prostate cancer.

Mehra N, Penning M, Maas J, van Daal N, Giles RH, Voest EE. Mehra N, et al. Among authors: voest ee. Clin Cancer Res. 2007 Jan 15;13(2 Pt 1):421-6. doi: 10.1158/1078-0432.CCR-06-1087. Clin Cancer Res. 2007. PMID: 17255261

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

358 results

Search Page